Influenza virus vaccine (Agriflu) - Novartis

Drug Profile

Influenza virus vaccine (Agriflu) - Novartis

Alternative Names: Agriflu

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Vaccines
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 20 Mar 2015 The vaccine is approved in the US and is in phase-III development in Chile
  • 02 Feb 2012 Novartis completes enrolment in its phase III trial for prevention of Influenza virus infections (in children) in Chile (NCT01346592)
  • 30 Apr 2011 Phase-III clinical trials in prevention of Influenza virus infections (in children) in Chile (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top